Rocket


Overview
Financials
News + Filings
IR Vault
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Filed Chapter 11
Quarterly results
Appointed director

OSCIENT PHARMACEUTICALS CORP (OSCI) Create: Alert

All | News | Filings
Date FiledTypeDescription
07/13/2009 8-K Quarterly results
06/22/2009 8-K Other Events
06/16/2009 8-K Cost Associated with Exit or Disposal Activities, Other Events, Financial Statements and Exhibits
Docs: "Oscient Pharmaceuticals Discontinues Sales Force Promotion for ANTARA and FACTIVE"
05/22/2009 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and...
Docs: "Oscient Pharmaceuticals Receives NASDAQ Letter Regarding Delay in Filing Form 10-Q Waltham, Mass., May 22, 2009 - Oscient Pharmaceuticals Corporation has received notification from the Listings Qualifications Department of The NASDAQ Stock Market LLC that since the Company has not filed its Form 10-Q for the period ended March 31, 2009, the Company is no longer in compliance with Marketplace Rule 5250. The Company has 60 calendar days, or until July 20, 2009, to submit a plan to regain compliance. Following such submission, NASDAQ may provide the Company with up to 180 calendar days from the filing's due date, or until November 11, 2009, to regain compliance. If NASDAQ does not accept the Company's plan to regain compliance, the Company will receive written notification of delisting from N..."
05/15/2009 8-K Form 8-K -- Current report
05/01/2009 8-K Form 8-K -- Current report
03/27/2009 8-K Form 8-K -- Current report
03/25/2009 8-K Quarterly results
Docs: "Oscient Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Financial Results - Conference call scheduled for Thursday, March 26 at 8:30 AM ET -",
"NASDAQ Extends Temporary Suspension of Bid Price and Market Value of Publicly Held Shares Requirements; Oscient Compliance Period Extended to October 6, 2009"
03/23/2009 8-K Form 8-K -- Current report
02/13/2009 8-K Form 8-K -- Current report
02/03/2009 8-K Form 8-K -- Current report
01/15/2009 8-K Other Events, Financial Statements and Exhibits
Docs: "Oscient Pharmaceuticals and Ethypharm SA File Lawsuit Against Lupin for Infringement of ANTARA Patent"
12/23/2008 8-K Form 8-K -- Current report
12/16/2008 8-K Form 8-K -- Current report
11/28/2008 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Oscient Pharmaceuticals Announces Successful Completion of Convertible Debt Exchange Offer"
11/20/2008 8-K Other Events, Financial Statements and Exhibits
Docs: "Oscient Pharmaceuticals Announces Determination of the Consideration Issuable in its Exchange Offer"
11/07/2008 8-K Form 8-K -- Current report
11/04/2008 8-K Quarterly results
Docs: "Oscient Pharmaceuticals Reports Third Quarter 2008 Financial Results — Total revenues increase more than 40% from Q3 2007 — - Conference call with senior management scheduled for 8:30 AM today -"
10/23/2008 8-K Form 8-K -- Current report
10/03/2008 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial ...
Docs: "Oscient Pharmaceuticals Receives NASDAQ Notice"
08/01/2008 8-K Quarterly results
Docs: "Oscient Pharmaceuticals Reports Second Quarter 2008 Financial Results — Total revenues increase 27% from Q2 2007 — — Conference call with senior management scheduled for 8:30 AM today"
07/30/2008 8-K Other Events, Financial Statements and Exhibits
Docs: "Oscient Pharmaceuticals Promotes Mark A. Glickman to Senior Vice President, Sales and Marketing"
07/08/2008 8-K Other Events
06/02/2008 8-K Other Events
05/07/2008 8-K Quarterly results
Docs: "Oscient Pharmaceuticals Reports First Quarter 2008 Financial Results — Conference call with senior management scheduled for 8:30 AM today",
"Regulatory Filing for FACTIVE Tablets Submitted in Europe — Oscient Pharmaceuticals' partner, Menarini Group, seeks marketing approval for fluoroquinolone antibiotic"
04/16/2008 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
04/04/2008 8-K Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
03/17/2008 8-K Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
02/07/2008 8-K Other Events, Financial Statements and Exhibits
02/06/2008 8-K Quarterly results
Docs: "Oscient Pharmaceuticals Records 2007 Revenues of $80 Million; Reports Financial Results for Fourth Quarter and Fiscal Year 2007 — Conference call with senior management scheduled for 8:30 AM today"
01/14/2008 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
12/10/2007 8-K Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers, Financial Statements ...
12/03/2007 8-K Other Events, Financial Statements and Exhibits
10/31/2007 8-K Quarterly results
Docs: "Oscient Pharmaceuticals Reports Financial Results for Third Quarter 2007 — Total revenues increase more than 25% over Q3 2006; Nine-month revenues increase 96% from prior year reflecting ANTARA acquisition — - Conference call with senior management scheduled for 8:30 AM ET today -"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy